Publications (original articles or review articles) published in 2024 from OUS - Dept. of Gastroenterology (Div Medicine)
11 publications found
Frailty risk and treatment strategy in elderly-onset inflammatory bowel disease. A Norwegian nationwide population-based registry study
Dig Liver Dis (in press)
DOI 10.1016/j.dld.2024.02.002, PubMed 38433021
Liver stiffness and associated risk factors among people with a history of injecting drugs: a prospective cohort study
Subst Abuse Treat Prev Policy, 19 (1), 21
DOI 10.1186/s13011-024-00603-z, PubMed 38532435
Novel biomarker profiles to improve individual diagnosis and prognosis in patients with suspected inflammatory bowel disease: protocol for the Nordic inception cohort study (NORDTREAT)
BMJ Open, 14 (5), e083144
DOI 10.1136/bmjopen-2023-083144, PubMed 38754881
Virologic Response and Reinfection Following HCV Treatment among Hospitalized People Who Inject Drugs: Follow-Up Data from the OPPORTUNI-C Trial
Viruses, 16 (6)
DOI 10.3390/v16060858, PubMed 38932151
Exploring the foundations of a digital health information service for patients with inflammatory bowel disease: a mixed method study in Gravitate-Health
BMC Gastroenterol, 24 (1), 184
DOI 10.1186/s12876-024-03272-1, PubMed 38789953
Treatment completion and SVR in the context of HCV elimination: Time to let go of the reins?
Clin Infect Dis (in press)
DOI 10.1093/cid/ciae298, PubMed 38824443
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial
Clin Infect Dis, 78 (3), 582-590
DOI 10.1093/cid/ciad711, PubMed 37992203
Identification and validation of a blood- based diagnostic lipidomic signature of pediatric inflammatory bowel disease
Nat Commun, 15 (1), 4567
DOI 10.1038/s41467-024-48763-7, PubMed 38830848
Clinical course of ulcerative colitis: Frequent use of biologics and low colectomy rate first year after diagnosis-results from the IBSEN III inception cohort
Aliment Pharmacol Ther, 60 (3), 357-368
DOI 10.1111/apt.18097, PubMed 38837289
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study
Crohns Colitis 360, 6 (1), otae013
DOI 10.1093/crocol/otae013, PubMed 38544907
Dietary intake and nutritional status in patients with newly diagnosed inflammatory bowel disease: insights from the IBSEN III study
Scand J Gastroenterol, 59 (6), 652-660
DOI 10.1080/00365521.2024.2313056, PubMed 38356408